STK39 inhibits antiviral immune response by inhibiting DCAF1-mediated PP2A degradation
aDepartment of General Surgery, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211166, China
bZhongda Hospital, School of Medicine, Advanced Institute for Life and Health, Southeast University, Nanjing 210009, China
cThe Second Hospital Affiliated Wannan Medical College, Wuhu 241000, China
dNanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210009, China
eNational Health Commission Key Laboratory of Antibody Techniques & Department of Pathology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, China
fDepartment of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310020, China
gJiangsu Cancer Hospital, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing 210009, China
* Corresponding authors.
收起